These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27886815)

  • 21. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W
    Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients enrolled in large randomized clinical trials of antiplatelet treatment for prevention after transient ischemic attack or ischemic stroke are not representative of patients in clinical practice: the Netherlands Stroke Survey.
    Maasland L; van Oostenbrugge RJ; Franke CF; Scholte Op Reimer WJ; Koudstaal PJ; Dippel DW;
    Stroke; 2009 Aug; 40(8):2662-8. PubMed ID: 19556533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials.
    Kwok CS; Shoamanesh A; Copley HC; Myint PK; Loke YK; Benavente OR
    Stroke; 2015 Apr; 46(4):1014-23. PubMed ID: 25721018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
    Dugani S; Ames JM; Manson JE; Mora S
    Curr Atheroscler Rep; 2018 Feb; 20(3):15. PubMed ID: 29464356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelets in stroke prevention.
    Pinto A; Di Raimondo D; Tuttolomondo A; Buttà C; Licata G
    Curr Vasc Pharmacol; 2013 Nov; 11(6):803-11. PubMed ID: 24484461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
    Cavender MA; Scirica BM; Bonaca MP; Angiolillo DJ; Dalby AJ; Dellborg M; Morais J; Murphy SA; Ophuis TO; Tendera M; Braunwald E; Morrow DA
    Circulation; 2015 Mar; 131(12):1047-53. PubMed ID: 25681464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy for secondary prevention of acute coronary syndrome, transient ischemic attack, and noncardioembolic stroke in an era of cost containment.
    Kessler C; Thomas K; Kao J
    J Investig Med; 2012 Jun; 60(5):792-800. PubMed ID: 22460233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiplatelet agents in secondary prevention of stroke].
    De Gautard G; Perrier A
    Rev Med Suisse; 2014 Oct; 10(446):1902, 1904-7. PubMed ID: 25438372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
    Bohula EA; Aylward PE; Bonaca MP; Corbalan RL; Kiss RG; Murphy SA; Scirica BM; White H; Braunwald E; Morrow DA
    Circulation; 2015 Nov; 132(20):1871-9. PubMed ID: 26338971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Secondary prevention with antiplatelet therapy in cardiac rehabilitation].
    Wanitschek MM; Alber HF
    Wien Med Wochenschr; 2018 Feb; 168(1-2):16-22. PubMed ID: 28091972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Secondary prophylaxis of stroke from a neurological perspective].
    Seidel G
    Herz; 2013 May; 38(3):251-60. PubMed ID: 23471343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
    Rothlisberger JM; Ovbiagele B
    J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    Liao JK
    Circulation; 2007 Mar; 115(12):1615-21. PubMed ID: 17389280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
    Bhatt DL; Bonaca MP; Bansilal S; Angiolillo DJ; Cohen M; Storey RF; Im K; Murphy SA; Held P; Braunwald E; Sabatine MS; Steg PG
    J Am Coll Cardiol; 2016 Jun; 67(23):2732-2740. PubMed ID: 27046160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction.
    Yeh RW; Kereiakes DJ; Steg PG; Windecker S; Rinaldi MJ; Gershlick AH; Cutlip DE; Cohen DJ; Tanguay JF; Jacobs A; Wiviott SD; Massaro JM; Iancu AC; Mauri L;
    J Am Coll Cardiol; 2015 May; 65(20):2211-21. PubMed ID: 25787199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.